NervGen Pharma: Stocks Analysts Recently Downgraded on TSX-V (NGEN)
NervGen Pharma Corp is among the group of TSX Venture Exchange stocks recently downgraded by analysts. This means each stock on this list has seen its averge consensus value drop in the last week so at least one analyst has downgraded their view on these stocks.
This report is generated monthly. It displays the number of analysts along with their buy-hold-sell ratings for the company. A company is included in this list when its mean rating decreases from the previous week. Stocks in this category are generally sold to preserve capital.
Companies can get downgraded for a number of reasons - but primarily due to reduced future earnings potential due to loss of contracts, new faltering product lines or increasing costs relative to revenue or financial risk.
| Symbol | Name | Buy | Out Perform | Hold | Under Perform | Sell | No Opinion | Mean Rating | Prev Mean Rating | Mean Label |
|---|---|---|---|---|---|---|---|---|---|---|
| NGEN | NervGen Pharma Corp | 1 | 1 | 1 | 0 | 0 | 0 | 4 | 4.5 | Outperform |
All data provided as of June 26, 2024.
More about NervGen Pharma Corp
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.
NervGen Pharma Corp is listed under NGEN on the TSX Venture Exchange.
Artificial intelligence at Report on Business
Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
